liraglutide produced 9.0% in the same trial
However, "stronger" also means stronger side effects, with discontinuation rates of 12-18% for retatrutide versus 5-7% for semaglutide
In Phase 2 studies, it led to a bigger average weight drop (about 24%) than Tirzepatide (about 21%)
Serial blood samples were collected for PK analysis at pre-specified intervals up to 672 h after the final dose (pre-dose, 4, 6, 12, 24, 36, 48, 72, 120, 168, 336, and end-of-study at 672 h)
Semaglutide doesn't directly affect thyroid hormone production, but it may alter levothyroxine absorption through delayed gastric emptying
The fact that retatrutide addresses multiple cardiovascular risk factors simultaneouslyweight, blood pressure, lipids, and inflammationsuggests it could have profound impacts on long-term health outcomes